Cargando…
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116334/ https://www.ncbi.nlm.nih.gov/pubmed/33980831 http://dx.doi.org/10.1038/s41408-021-00478-4 |
| _version_ | 1783691381675393024 |
|---|---|
| author | Mikhael, Joseph Belhadj-Merzoug, Karim Hulin, Cyrille Vincent, Laure Moreau, Philippe Gasparetto, Cristina Pour, Ludek Spicka, Ivan Vij, Ravi Zonder, Jeffrey Atanackovic, Djordje Gabrail, Nashat Martin, Thomas G. Perrot, Aurore Bensfia, Samira Weng, Qilong Brillac, Claire Semiond, Dorothée Macé, Sandrine Corzo, Kathryn P. Leleu, Xavier |
| author_facet | Mikhael, Joseph Belhadj-Merzoug, Karim Hulin, Cyrille Vincent, Laure Moreau, Philippe Gasparetto, Cristina Pour, Ludek Spicka, Ivan Vij, Ravi Zonder, Jeffrey Atanackovic, Djordje Gabrail, Nashat Martin, Thomas G. Perrot, Aurore Bensfia, Samira Weng, Qilong Brillac, Claire Semiond, Dorothée Macé, Sandrine Corzo, Kathryn P. Leleu, Xavier |
| author_sort | Mikhael, Joseph |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8116334 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81163342021-05-14 A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab Mikhael, Joseph Belhadj-Merzoug, Karim Hulin, Cyrille Vincent, Laure Moreau, Philippe Gasparetto, Cristina Pour, Ludek Spicka, Ivan Vij, Ravi Zonder, Jeffrey Atanackovic, Djordje Gabrail, Nashat Martin, Thomas G. Perrot, Aurore Bensfia, Samira Weng, Qilong Brillac, Claire Semiond, Dorothée Macé, Sandrine Corzo, Kathryn P. Leleu, Xavier Blood Cancer J Correspondence Nature Publishing Group UK 2021-05-12 /pmc/articles/PMC8116334/ /pubmed/33980831 http://dx.doi.org/10.1038/s41408-021-00478-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Mikhael, Joseph Belhadj-Merzoug, Karim Hulin, Cyrille Vincent, Laure Moreau, Philippe Gasparetto, Cristina Pour, Ludek Spicka, Ivan Vij, Ravi Zonder, Jeffrey Atanackovic, Djordje Gabrail, Nashat Martin, Thomas G. Perrot, Aurore Bensfia, Samira Weng, Qilong Brillac, Claire Semiond, Dorothée Macé, Sandrine Corzo, Kathryn P. Leleu, Xavier A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab |
| title | A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab |
| title_full | A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab |
| title_fullStr | A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab |
| title_full_unstemmed | A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab |
| title_short | A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab |
| title_sort | phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116334/ https://www.ncbi.nlm.nih.gov/pubmed/33980831 http://dx.doi.org/10.1038/s41408-021-00478-4 |
| work_keys_str_mv | AT mikhaeljoseph aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT belhadjmerzougkarim aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT hulincyrille aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT vincentlaure aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT moreauphilippe aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT gasparettocristina aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT pourludek aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT spickaivan aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT vijravi aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT zonderjeffrey aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT atanackovicdjordje aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT gabrailnashat aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT martinthomasg aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT perrotaurore aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT bensfiasamira aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT wengqilong aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT brillacclaire aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT semionddorothee aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT macesandrine aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT corzokathrynp aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT leleuxavier aphase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT mikhaeljoseph phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT belhadjmerzougkarim phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT hulincyrille phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT vincentlaure phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT moreauphilippe phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT gasparettocristina phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT pourludek phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT spickaivan phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT vijravi phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT zonderjeffrey phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT atanackovicdjordje phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT gabrailnashat phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT martinthomasg phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT perrotaurore phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT bensfiasamira phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT wengqilong phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT brillacclaire phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT semionddorothee phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT macesandrine phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT corzokathrynp phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab AT leleuxavier phase2studyofisatuximabmonotherapyinpatientswithmultiplemyelomawhoarerefractorytodaratumumab |